TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
23/04/2026
Voltar para busca
Dado oficial do USPTO
ETHERNA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ETHERNA
ST13
US500000097728325Classe
1, 5, 40, 42
Pedido
97728325
Registro
7634843
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
24/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 40, 42
Data de depósito
22/12/2022
Data de registro
31/12/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
31/12/2024
Última transação
24/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
30/10/2013
Primeiro uso no comércio
30/10/2013
Código do desenho
4
Tipo de titular
99
Localização do titular
Niel, BE
Examinador
EDWARDS, ALICIA COLLINS
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
eTheRNA immunotherapies NV
Representantes
Cheryl L. Burbach Erise IP, P.A.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Biological preparations for scientific and research purposes for boosting cells in the immune system for improved therapies; biological preparations for scientific and research purposesa mRNA-based composition for enhancing immunities; biological preparations in the nature of genetically modified cells and vectors for scientific and research purposes; biological and chemical reagents including complexes of these molecules for research purposesfor clinical researchclinical chemistryclinical trialsscientific researchmedical researchlaboratory researchfor industrial usefor use in the manufacture of pharmaceuticals
Classe 5
Vaccines; vaccine adjuvants; medicalbiologicalpharmaceutical preparations for medical usepreparations containing messenger RNA for preventing and treating virusesmedical disordersdiseasesviral infectionsbacterial infectionscancerviralbacterialmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; mRNA-based therapeutics and therapeutic agents for in prevention and treatment of virusesmedical disordersdiseasesviral infectionsbacterial infectionscancerviralbacterialmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; lipid nanoparticles for pharmaceuticalmedical or diagnostic purposes for preventing and treating virusesmedical disordersdiseasesviral infectionsbacterial infectionscancerviralbacterialmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; drug carriers for medical usedrug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; lipid nanoparticles for drug delivery sold as an integral component of drugs in the nature of pharmaceutical preparations for preventing and treating virusesmedical disordersdiseasesviral infectionsbacterial infectionscancerviralbacterialmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; pharmaceutical preparationsmessenger RNA and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells for preventing and treating virusesmedical disordersdiseasesviral infectionsbacterial infectionscancerviralbacterialmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders
Classe 40
Custom manufacture of pharmaceutical and medical preparations; custom manufacture of mRNA molecules; custom manufacture of mRNA molecules formulated in lipid nanoparticles; custom manufacture of mRNA for use in vaccinescell therapygene editingprotein replacementantibodies; provision of informationadvice and consultancy services relating to all of the aforesaid
Classe 42
Scientific research and development; pharmaceutical research and development services; medical research and development services; scientificpharmaceuticalmedical research and development in the field of mRNA therapeutics; scientificpharmaceuticalmedical research and development in the field of proprietary lipids and lipid nanoparticle formulations for the delivery of mRNA therapeutics for the treatment of various medical disorderscancerinfectious diseases
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
23/04/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
23/04/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
23/04/2026
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
23/04/2026
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
23/04/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
31/12/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
31/12/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/12/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
10/12/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
22/10/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
22/10/2024
IUAF
USE AMENDMENT FILED
16/08/2024
EISU
TEAS STATEMENT OF USE RECEIVED
16/08/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
13/08/2024
EX1G
SOU EXTENSION 1 GRANTED
13/08/2024
EXT1
SOU EXTENSION 1 FILED
13/08/2024
EEXT
SOU TEAS EXTENSION RECEIVED
13/08/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
27/02/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/01/2024
PUBO
PUBLISHED FOR OPPOSITION
02/01/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
13/12/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/11/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/10/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
26/10/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
26/10/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/10/2023
GNRT
NON-FINAL ACTION E-MAILED
06/10/2023
CNRT
NON-FINAL ACTION WRITTEN
06/10/2023
DOCK
ASSIGNED TO EXAMINER
22/09/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/01/2023
NWAP
NEW APPLICATION ENTERED
26/12/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ETHERNA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.